Precision BioSciences to Report Fourth Quarter and Fiscal Year 2024 Results on March 26, 2025
DURHAM, N.C., March 21, 2025--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies, including gene elimination, gene insertion, and gene excision programs, today announced that it will publish financial results for the fourth quarter and fiscal year 2024 and provide a business update on March 26, 2025.
About Precision BioSciences, Inc.
Precision BioSciences, Inc. is a clinical stage gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform that differs from other technologies in the way it cuts, its smaller size, and its simpler structure. Key capabilities and differentiating characteristics may enable ARCUS nucleases to drive more intended, defined therapeutic outcomes. Using ARCUS, the Company's pipeline is comprised of in vivo gene editing candidates designed to deliver lasting cures for the broadest range of genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences, please visit www.precisionbiosciences.com.
The ARCUS® platform is being used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome e.g. viral DNA or mutant mitochondrial DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single AAV).
View source version on businesswire.com: https://www.businesswire.com/news/home/20250321857482/en/
Contacts
Investor and Media Contact: Naresh TannaVice President of Investor Relationsnaresh.tanna@precisionbiosciences.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
41 minutes ago
- Business Wire
DigitalOcean and AMD Collaborate to Advance AI Using Cloud-Based GPUs
NEW YORK--(BUSINESS WIRE)-- DigitalOcean Holdings, Inc. (NYSE: DOCN), the simplest scalable cloud for digital native enterprises, today announced a collaboration with AMD that provides DigitalOcean customers with access to AMD Instinct™ GPUs as DigitalOcean GPU Droplets to power their AI workloads starting with the AMD MI300X GPUs. Later this year, DigitalOcean will offer AMD Instinct™ MI325X GPUs, further expanding access to powerful and affordable GPU models. AMD Instinct™ MI325X GPU accelerators set new AI performance standards, delivering incredible performance and efficiency for training and inference. AMD Instinct MI300X GPUs deliver leadership performance for accelerated high-performance computing (HPC) applications and the newly exploding demands of generative AI. With the AMD ROCm™ software platform, customers can develop powerful HPC and AI production-ready systems faster than ever before. Its large memory capacity allows it to hold models with hundreds of billions of parameters entirely in memory, reducing the need for model splitting across multiple GPUs. By combining powerful AMD AI compute engines and DigitalOcean's cloud technologies, the collaboration aims to empower the massive community of digital native enterprises to integrate AI into their applications and support the most demanding AI workloads at scale. These next-generation GPUs have already been available in bare metal configurations for customers seeking increased control and computing power. These GPUs are now also available as GPU Droplets or as DigitalOcean Kubernetes worker nodes. The GPU Droplets are available both as single and eight GPU configurations, allowing customers to optimize costs for their specific use cases. Accessing these GPU Droplets through DigitalOcean offers several key benefits, including competitive pricing at $1.99/GPU per hour, a simple setup process, and enterprise-grade SLAs. While other cloud providers require multiple steps and deep technical knowledge to configure security, storage, and network requirements, DigitalOcean's GPU Droplets can be set up with just a few clicks. In addition to these new GPUs, customers will also have access to AMD Developer Cloud, a new platform powered by DigitalOcean that is purpose-built for rapid, high-performance AI development. Customers will have access to a fully managed environment that provides instant access to AMD Instinct MI300X GPUs—with zero hardware investment or local setup required. Whether fine-tuning LLMs, benchmarking inference performance, or building a scalable inference stack, the AMD Developer Cloud provides the tools and flexibility to get started instantly—and grow without limits. 'DigitalOcean's collaboration with AMD is another proof point to make AI easily accessible to our customers,' said Bratin Saha, Chief Product & Technology Officer at DigitalOcean. 'With access to AMD GPUs, DigitalOcean customers have an extensive portfolio of GPUs with the flexibility of the computing configuration that best suits their requirements.' "At AMD, we are proud to work with DigitalOcean to provide developers with cutting-edge solutions for developer enablement and demanding workloads that require large amounts of memory,' said Negin Oliver, corporate vice president of business development, Data Center GPU Business, at AMD. 'Together, AMD and DigitalOcean are committed to providing the critical innovative technologies required to support the evolving needs of growing tech businesses.' To access AMD Instinct GPUs with DigitalOcean, visit the DigitalOcean website. DigitalOcean is the simplest scalable cloud platform that democratizes cloud and AI for digital native enterprises around the world. Our mission is to simplify cloud computing and AI to allow builders to spend more time creating software that changes the world. More than 600,000 customers trust DigitalOcean to deliver the cloud, AI, and ML infrastructure they need to build and scale their organizations. To learn more about DigitalOcean, visit
Business Wire
41 minutes ago
- Business Wire
Sabra Health Care REIT, Inc. Thanks Clifton J. Porter II for His Board Service
TUSTIN, Calif.--(BUSINESS WIRE)-- Rick Matros, the Chair and Chief Executive Officer of Sabra Health Care REIT, Inc. ('Sabra' or the 'Company') (Nasdaq: SBRA), issued the following statement today thanking Clifton J. Porter II for his five years of Board service to the Company: 'On behalf of our Board of Directors, I want to thank Clif for his exemplary service to our Company. I know our Board and leadership team benefited greatly from his insights and expertise—I certainly did. We look forward to continuing to work with Clif in his capacity as the President and CEO of the American Health Care Association/National Center for Assisted Living (AHCA/NCAL), where we know he will continue to provide great leadership for the healthcare industry.' Sabra Health Care REIT, Inc. Thanks Clifton J. Porter II for his Board Service. Share Mr. Porter stated, 'These past five years on the Sabra Board have been one of the highlights of my career. It has been a rewarding experience to work with such an accomplished group of leaders. An operational culture drives Sabra and I am confident that the organization will continue to flourish. I look forward to continuing to support Sabra's mission in my new role.' About Sabra Sabra Health Care REIT, Inc., a Maryland corporation, operates as a self-administered, self-managed real estate investment trust (a 'REIT') that, through its subsidiaries, owns and invests in real estate serving the healthcare industry throughout the United States and Canada.
Business Wire
41 minutes ago
- Business Wire
Rosen Law Firm Encourages GeneDx Holdings Corp. Investors to Inquire About Securities Class Action Investigation
NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of GeneDx Holdings Corp. (NASDAQ: WGS) resulting from allegations that GeneDx may have issued materially misleading business information to the investing public. So What: If you purchased GeneDx securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses. What to do next: To join the prospective class action, go to or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@ for information on the class action. What is this about: On February 5, 2025, Grizzly Research published a report entitled 'Insiders Attest that GeneDx (Nasdaq: WGS) Is Actively Committing Widespread Fraud.' This report stated that Grizzly believed that GeneDx's 'growth is largely an illusion, driven by fraudulent schemes and illegal tactics deliberately aimed at exploiting Medicaid and Medicare systems to artificially inflate revenue.' On this news, GeneDx stock fell 6.7% on February 5, 2025. Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. At the time, Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone, the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by Law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. Follow us for updates on LinkedIn: on Twitter: or on Facebook: Attorney Advertising. Prior results do not guarantee a similar outcome.
